Wegovy is a new and increasingly popular medication used for weight loss, functioning similarly to Ozempic, and is prescribed to individuals with excess body weight.

Questions are being raised about whether Novo Nordisk's stock rebound, driven by its drug Wegovy, is beginning to lose momentum.

Eli Lilly's weight-loss pill Foundayo has received approval in the U.K., marking its first approval outside the U.S. and intensifying its competition with Novo Nordisk's Wegovy.

An expert provides specific meal recommendations to achieve a natural 'weight loss drug effect,' similar to that of Wegovy.

New Zealand's Advertising Standards Authority investigated a complaint and found that a Wegovy advertisement on a digital billboard used a font size that was too small.

Novo Nordisk is gaining momentum with its Wegovy weight-loss pill, maintaining its lead against Eli Lilly's recently launched Foundayo in the competitive obesity treatment market.

A new trial indicates that the drug used in Ozempic and Wegovy pills could also be effective in treating alcohol use disorder, a condition for which no new medication has been approved since 2006.

Reports of side effects such as 'Ozempic face,' hair loss, and digestive problems are increasing as weight-loss medications like Wegovy and Mounjaro gain popularity, prompting research into their robustness.

A 57-year-old Romanian patient, Adriana Turea, describes her step-by-step experience with the injectable weight-loss drug Wegovy, after struggling with diets since age 18.

The weight-loss medication Wegovy is now available in tablet form, offering an alternative for individuals with needle phobia. Experts caution that the new pill is not a harmless lifestyle solution.

An opinion piece and recent reports highlight various negative consequences of using weight-loss injections such as Mounjaro, Wegovy, and Ozempic, including risks like damaged metabolism, muscle loss, and newly identified side effects like 'Ozempic feet'.

Vivani has entered into a pact with Novo to study the potential of a Wegovy implant.

The weight loss medication Wegovy has become available for purchase in the UK, offering a new option for individuals seeking to manage their weight.

Drugs such as Ozempic, Mounjaro, and Wegovy are showing effects well beyond weight loss and diabetes treatment, NOS

A new Medicare GLP-1 Bridge program, effective July 1, will reduce the cost of weight-loss drugs like Wegovy and Zepbound to $50 a month for eligible seniors.

Maria Sommer-Kosack was diagnosed with brain damage after experiencing severe vomiting and vitamin deficiency while taking the drug Wegovy, and has since received compensation.

An article examines whether Novo Nordisk A/S (NVO) is strengthening its leadership in the weight-loss market with the launch of its oral Wegovy.

The cybercrime group FulcrumSec claims to have stolen 1.3 TB of data from Novo Nordisk, the manufacturer of Ozempic and Wegovy, and is demanding a $25 million ransom after the company refused to pay.

New research suggests a curious connection between GLP-1 class medications, such as Ozempic and Wegovy, and an increased risk of violent behavior, adding to the growing list of potential effects beyond weight loss.

A Danish woman claims to have suffered brain damage and severe vitamin deficiency after using the weight-loss drug Wegovy, prompting the European Medicines Agency to investigate potential nerve damage as a side effect.

The global weight-loss drug market is experiencing a significant shift, with the focus moving from injectable medications to oral tablets, as new participants like Novo Nordisk's Wegovy pill gain rapid approval and market share.

A new lab-made antibody drug is being developed to help patients retain lean muscle tissue while using popular weight-loss injections like Ozempic and Wegovy. Researchers found this muscle-boosting drug could mitigate muscle atrophy, addressing a common concern with these slimming treatments.

Novo Nordisk's Wegovy pill has significantly surpassed market expectations, leading to discussions about the investment potential of the company's stock.

Novo Nordisk has announced a 19% price reduction for the higher doses of its obesity drug, Wegovy.

Experts are weighing in on concerns regarding a potential connection between the weight-loss drug Wegovy and an increased risk of eye stroke.

The South Korean government is moving to tighten access to injectable obesity medications like Wegovy and Mounjaro, closing prescription loopholes and cracking down on overseas purchases due to misuse concerns.

An egg-and-oil recipe is gaining traction in Korea as a cheaper alternative to weight-loss injections like Wegovy and Mounjaro, circulating widely on social media.

Scientists have discovered that GLP-1 based medications, such as Ozempic, Wegovy, and Mounjaro, significantly reduce the risk of cardiovascular events like heart attacks and strokes, in addition to their known benefits for diabetes and obesity.

The Wegovy pill from Novo Nordisk has received an important endorsement for approval from the European Medicines Agency, paving the way for its potential availability in Europe.

New research indicates that GLP-1 drugs, such as Ozempic and Wegovy, could potentially slow the spread of obesity-related cancers, leading to better outcomes for patients.

Pharmac, New Zealand's drug-buying agency, has placed the weight-loss drug Wegovy on its list of medicines suitable for future funding, with swift approval expected.

Danish pharmaceutical giant Novo Nordisk, producer of weight-loss drugs Ozempic and Wegovy, has announced it is abandoning plans to build a new factory in Denmark due to altered global market demand.

Novo Nordisk has announced that a higher-dose version of its weight-loss drug, Wegovy, helped some patients lose nearly 28% of their body weight. Early responders to the increased dosage showed additional significant weight reduction.

Medications like Wegovy or Ozempic help obesity patients lose weight by temporarily suppressing appetite, but permanent weight loss cannot be achieved solely through injections.

Scientists have discovered a naturally occurring molecule, using AI, that acts directly in the brain's appetite center and could offer a new treatment for obesity with fewer side effects.

A new study suggests that individuals with a common gene variant, associated with a sweet tooth, may lose weight more effectively using the slimming drug semaglutide (Wegovy). This discovery could pave the way for personalized weight loss treatments.

Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development  Reuters

New research indicates that an individual's genetic makeup, specifically variations in two genes linked to appetite and digestion, could be a determining factor in the effectiveness of popular weight loss medications such as Wegovy, Mounjaro, and Ozempic.

An overview of the rapidly growing GLP-1 market details the costs of popular weight-loss medications like Wegovy, Zepbound, and Foundayo, and offers advice on choosing the best option.

Novo Nordisk has launched the high-dose version of its GLP-1 injection, Wegovy, at a price point $50 lower than Eli Lilly's competing drug, Zepbound. This strategic pricing aims to position Wegovy competitively in the market.

Wegovy has introduced a new subscription service that could allow users to save up to $1,200 on the medication.

The British drug-cost watchdog has recommended the use of Novo Nordisk's drug Wegovy to help lower heart risks.

Novo Nordisk has reduced the prices of its popular drugs Ozempic and Wegovy in India, a move made in response to the growing threat of generic competition in the market.

Hims & Hers Health has announced it is now selling Novo Nordisk's popular weight-loss medications, Wegovy and Ozempic, expanding access to these treatments.

The FDA has approved Wegovy HD, a higher-dose semaglutide, for weight loss in adults with obesity, offering a 'major jump' in potential weight reduction, with some users losing an average of 21 percent of their body weight.

Novo Nordisk’s Higher Dose Wegovy Weight-Loss Drug Gains U.S. Approval  WSJ

US FDA approves higher dose of Novo's Wegovy under new fast-track review program  Reuters

Drugs like Ozempic, Wegovy, or Mounjaro have changed the game. In some patients, they lead to weight loss, which was practically unattainable without surgery until recently.

This experimental pill helped people lose about 16% of their body weight after about a year of treatment

Antidiabetic drugs, such as Ozempic and Wegovy, have recently gained immense popularity as weight loss agents.

Novo Nordisk’s Wegovy tablet offers Danish drugmaker window to win back market share from Eli Lilly

STUDIJA je otkrila da lijek za mršavljenje Wegovy nosi gotovo pet puta veći rizik od iznenadnog gubitka vida, tzv. 'očnog udara', u usporedbi s lijekom za dijabetes Ozempic.

‘Eye strokes’ that reduce blood flow to optic nerve likely to be side-effect of active ingredient semaglutide, says author Patients taking Wegovy have nearly five times the risk of sudden sight loss…

Novo Nordisk is implementing price reductions for its popular drugs Ozempic and Wegovy, a strategic move that analysts suggest could ultimately benefit the company's stock performance.

Novo Nordisk has announced price reductions of up to 17.6% for its diabetes and obesity drugs, Ozempic and Wegovy, in Spain, with Wegovy's highest dose dropping to 223.64 euros.

Data from the National Association of Pharmacies indicates a significant increase in obesity medication sales in 2025, largely driven by the market entry of Mounjaro and Wegovy in Portugal.

Danish drugmaker Novo Nordisk is investing in a new facility in Ireland to expand its production capacity for the newly launched weight-loss pill Wegovy, aiming to compete with Eli Lilly.

Novo Nordisk is reportedly investing $507 million in a new plant for its Wegovy pill, as reported by the Irish Times.

Celebrities like Chrissy Metz and Serena Williams are among those discussing the use of GLP-1 weight loss injectables such as Ozempic, Mounjaro, and Wegovy, highlighting the public's growing engagement with these medications.

The first weight-loss tablet, Wegovy, is scheduled to be released in Germany in a few weeks, with a diabetologist explaining its suitability and potential side effects.

Germany is discussing whether health insurance should cover weight-loss injections like Wegovy, Mounjaro, and Ozempic, with experts advocating for a relaxation of current regulations.

GLP-1 medications such as Ozempic and Wegovy are being studied for their potential beyond weight loss, specifically their ability to reduce cravings for alcohol and other addictive substances. Some users of these drugs have reported that their desire for alcohol disappeared or that they experienced nausea when drinking.

The CEO of Novo Nordisk has adjusted expectations for the explosive growth of its popular weight-loss drug, Wegovy.

Novo Nordisk A/S Chief Executive Officer Mike Doustdar talks about the company's performance as its popular Wegovy weight-loss pill disappointed investors with sales that failed to live up to the…

Research continues to reveal less-known side effects of GLP-1 weight-loss drugs like Ozempic and Wegovy, beyond common issues like nausea, with new findings highlighting potential impacts on kidney function, hair loss, and menstrual changes.

The European Commission has approved Wegovy in tablet form, making it the first oral GLP-1 receptor agonist for treating obesity and overweight in EU countries, previously only available as an injectable.

The Guardian is seeking input from readers who have used GLP-1 drugs such as Wegovy and Mounjaro for weight loss but have not experienced the desired effects, acknowledging that these drugs are ineffective for a small percentage of users.

Danish manufacturer Novo Nordisk announced it is seeking a provisional injunction from a US court to immediately block advertisements for obesity and diabetes drugs by American company Eli Lilly. The lawsuit involves popular medications like Wegovy, Ozempic, Mounjaro, and Zepbound.

The weight-loss drug Wegovy is set to become available in tablet form, offering an alternative to injections. While this is good news for those with needle phobia, daily intake presents its own challenges.

The Wegovy pill has received approval in Europe, marking a new era in the treatment of obesity. This approval introduces the first weight-loss tablet to the market, offering a new therapeutic option.

The new Wegovy weight-loss pill has gone on sale in UK pharmacies, sparking a debate among readers about its effectiveness, the role of willpower, and preferences for different weight-loss methods.

Researchers at the Wistar Institute in Philadelphia have developed a novel method for delivering drugs for obesity and type 2 diabetes, aiming to replace the need for frequent injections like Ozempic or Wegovy. The effectiveness of this new approach is still undergoing evaluation.

Earlier this year, Danish pharmaceutical company Novo Nordisk's obesity drug Wegovy was denied a subsidy in Sweden.

The Wegovy weight-loss medication, manufactured by Novo Nordisk, has gone on sale at high street and online pharmacies across the UK, though it is not yet available through the NHS.

Danish commentators are cautioning against the royal family adopting a 'Wegovy-kongehus' image, suggesting that a weight-loss focus might not be healthy for the monarchy.

A podcast discusses the 'bycatch' or additional effects of weight-loss medications like Ozempic, Mounjaro, and Wegovy. Users report experiencing more than just reduced hunger and weight loss, indicating broader impacts.

Novo Nordisk, the maker of the weight-loss drug Wegovy, is actively lobbying insurers to cover the significant cost of its weight loss injections. Employers and health plans have shown reluctance to cover these expensive medications.

The Wegovy weight-loss pill has been approved for sale in the UK, with a study predicting that one in eight Britons will be taking the medication by 2027, influencing consumer spending habits.

Oral Wegovy has secured one-third of all prescriptions as its adoption continues to accelerate in the market.

Anti-obesity centers in France are bracing for a surge in new patients following the June 15 decision to reimburse Wegovy and Mounjaro by social security under strict conditions.

Novo Nordisk has achieved a significant milestone, marking more than 3 million prescriptions for its weight-loss drug, Wegovy, in pill form.

A report indicates that 80% of Wegovy pill users had no prior experience with weight loss drugs, prompting questions about its potential impact on Novo Nordisk's market valuation.

The Danish government plans to examine whether the weight-loss medication Wegovy can help more people enter the workforce, as part of a broader business update.

France will begin to reimburse weight loss injections from June 15. This was announced by Health Minister Stéphanie Rist, saying that the state will reimburse 65% of the cost of Wegovy injections and...

Novo Nordisk presented encouraging new data at the European Congress on Obesity, indicating up to 27.7% weight loss with a new high dose of semaglutide (Wegovy).

A new study by American scientists investigates why drugs like Ozempic and Wegovy lead to different weight loss outcomes among individuals, and why weight loss often plateaus after months of use.

GLP-1 drugs, known by names like Ozempic, Wegovy, and Mounjaro, offer benefits to the heart, kidneys, and liver, independent of weight loss. These broader effects, previously observed in animals, are now being seen in humans.

The European Medicines Agency (EMA) has recommended the approval of Wegovy in pill form, a significant step for the weight-loss medication.

Countries representing 40% of the world's population are set to gain access to generic versions of Ozempic and Wegovy, potentially costing as little as $15 a month, while the U.S. currently lacks these generics.

An opinion piece reflects on the use of the weight-loss drug Wegovy, suggesting that societal discussions once focused on unhealthy lifestyles now point to a lack of spirit and competence.

Icelandic health authorities are cautioning the public about the sale of weight-loss drugs like Wegovy and Ozempic through unofficial online channels, citing concerns over unknown substances.

Pharmaceutical giant Novo Nordisk is leveraging its weight-loss drug Wegovy to offset declining sales and strengthen its position in the competitive weight-loss market. The success of Wegovy is providing the company with a renewed opportunity for market supremacy.

Early performance of Novo Nordisk's Wegovy pill is prompting investors to reconsider Eli Lilly & Co.'s previously assumed dominance in the GLP-1 pill market.

New obesity medications, Foundayo and Wegovy, are soon to be available in the UAE, prompting discussions about whether health insurance will cover their costs.

Finland's price board has rejected a pharmaceutical company's application for basic reimbursement of the obesity drug Wegovy, meaning patients will continue to bear the full cost.

Novo Nordisk, maker of Wegovy and Ozempic, is strategizing a comeback in the US market for its weight-loss drugs, aiming to learn from consumer groups to improve its approach.

Research suggests that GLP-1 drugs such as Ozempic and Wegovy could potentially double the risk of divorce, a trend observed previously in bariatric surgery patients, according to expert warnings.

Research suggests that an individual's genetic predisposition can play a role in how effectively weight-loss medications such as Wegovy and Mounjaro work, with some people losing less weight even with medication.

Novo Nordisk's weight-loss drug, Wegovy, is set to become available to an additional 1.2 million patients across England.

Novo Nordisk has once again reduced the prices of its popular drugs Ozempic and Wegovy in India, a strategic move aimed at competing with cheaper generic alternatives in the market.

Generic versions of popular weight-loss medications like Ozempic and Wegovy are anticipated to become available in Canadian pharmacies this summer, offering more affordable alternatives to patients currently paying $300-$400 monthly for brand-name drugs. This development could significantly impact access and cost for weight management treatments.

People taking ‘Wegovy HD’ lost an average of 21 percent of their body weight after 72 weeks

The FDA has approved Wegovy HD, a higher-dose semaglutide, for weight loss in adults with obesity, promising greater weight reduction despite expert warnings about potential side effects.

The patents for popular drugs Ozempic and Wegovy are expiring in various countries, paving the way for the production of generic versions to begin as early as this weekend.

Novo Nordisk's weight-loss drug, Wegovy, has received approval from U.S. regulators for a higher dose. This development expands the treatment options available for weight management.

Jót tehet a szívének a Wegovy, az Ozempic és a többi, GLP-1-alapú gyógyszer, de a hatás nem tart örökké, csak addig, amíg szedi őket.

V Indiji poteče patent za semaglutid – učinkovino v zdravilih Wegovy in Ozempic podjetja Novo Nordisk. Bo to spremenilo globalno sliko zdravljenja debelosti?

American restaurant chains are reconsidering both menus and portion sizes after the use of so-called GLP-1 drugs, such as Ozempic, Wegovy, and Zepbound, has increased significantly.

Researchers reveal that generic injectable semaglutide, the main ingredient in Ozempic and Wegovy, could cost between $28 and $140 (about 24 and 121 euros) per year.

Wegovy may carry the highest risk of “eye stroke” and sudden sight loss of weight-loss jabs, according to a new analysis.

The American authority notes alleged gaps in procedures for adverse reactions in the use of drugs for diabetes and obesity. The Danish giant launches a plan to correct course

New study suggests GLP-1 drugs like Ozempic and Wegovy may raise fracture risk by 11% in adults 65 and older with type 2 diabetes compared to other diabetes medications.

Pounds melt away with weight loss injections. However, the treatment will likely have to be continued lifelong, otherwise the weight threatens to increase rapidly again. A small deficit can possibly be saved.

Novo Nordisk, the company behind the injectable weight-loss drug Wegovy, plans to invest €430 million in its Athlone plant to enhance the production of Wegovy in pill form.

Pharmaceutical company Novo Nordisk announced a €430 million expansion of its manufacturing operation in Athlone, Ireland, to produce the tablet form of its weight loss drug Wegovy.

Jim Cramer is reevaluating Novo Nordisk (NVO) as the adoption of its Wegovy pill accelerates, indicating a potential shift in market dynamics.

The New Zealand dairy industry is experiencing a boom, capitalizing on a surge in global demand for bioactive proteins like whey, which is driven by the increasing popularity of weight-loss drugs such as Wegovy.

Novo Nordisk is making a significant push for its Wegovy pill, which has been a strong competitor against Eli Lilly. However, following a supply crisis in 2021, analysts are questioning whether production can keep pace with the high demand.

GLP-1 medications like Ozempic and Wegovy are being studied for their potential beyond weight loss, specifically their ability to reduce cravings for alcohol and other addictive substances by affecting a specific brain region.

Novo Nordisk, which became Europe's most valuable company thanks to its weight loss drug Wegovy, is now reportedly struggling to identify its next major blockbuster pharmaceutical.

A Danish pharmaceutical giant has announced increased operating profit for the second quarter, driven by robust sales of its tablet-form drug, Wegovy, leading to a raised earnings forecast.

A breast cancer surgeon suggests that popular GLP-1 weight-loss drugs like Ozempic and Wegovy may help lower the risk of cancer recurrence by reducing BMI, estrogen levels, and inflammation.

The European Commission has approved Wegovy in tablet form as the first oral GLP-1 receptor agonist for the treatment of obesity and overweight in EU countries, marking a breakthrough in pharmacological tools against obesity.

An Austrian woman shares her experience using weight-loss injections since May, noting their increasing popularity despite high costs. The introduction of new medications like Wegovy could potentially lower prices.

An analysis suggests that GLP-1 weight-loss medications like Wegovy and Mounjaro could significantly decrease the risk of alcohol-related hospital admissions by 26%.

Novo Nordisk has expanded its franchise with the first European approval for its oral weight loss drug, Wegovy, marking a significant development in the treatment of obesity.

India's drug regulator, CDSCO, has granted approval for Novo Nordisk's weight-loss drug Wegovy (semaglutide injection 2.4 mg) to treat noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults.

Neurologists are warning that GLP-1 weight-loss drugs like semaglutide (Ozempic, Wegovy) may accelerate the progression of ALS by triggering dangerous rapid weight loss in patients with brain disorders.

An opinion piece discusses the negative consequences of using weight-loss injections like Mounjaro, Wegovy, and Ozempic, highlighting risks such as damaged metabolism and muscle loss despite initial weight reduction.

The demand for weight loss medications is expected to increase significantly with the introduction of pill forms, such as Wegovy, in addition to existing injectable treatments like Ozempic and Mounjaro. The article discusses how these drugs work and their associated risks.

Scientists at the Endocrine Society congress presented a systematic review of clinical studies, revealing a new groundbreaking effect of weight-loss drugs like Ozempic, Wegovy, and Mounjaro in men, beyond their primary role in weight reduction.

An article discusses Ozempic and Wegovy, two medications containing the same active substance, semaglutide, but highlights their distinct intended uses and applications.

Scientists at the Wistar Institute in Philadelphia have developed a new method for delivering obesity and type 2 diabetes drugs, which could potentially replace the need for frequent, repetitive injections like Ozempic or Wegovy. Its effectiveness still needs to be confirmed.

Davor Skeledžija, from the Association for the Promotion of Patient Education, participated in a European Parliament event on obesity. The discussion highlighted that France covers Mounjaro and Wegovy, Italy has enacted an obesity law, while Croatia is lagging in its approach.

Strong sales of the weight-loss drug Wegovy are anticipated to potentially trigger an upward revision of financial forecasts for pharmaceutical giant Novo Nordisk.

Novo Nordisk's Wegovy pill has reached 3 million prescriptions, prompting questions about whether Wall Street is underestimating the beaten-down stock.

The French healthcare system is now reimbursing anti-obesity drugs like Wegovy and Mounjaro under strict conditions, prompting discussions on France's obesity rates and affected regions.

The anti-obesity medications Mounjaro and Wegovy are becoming more prevalent in France, now covered by social security for individuals with obesity or diabetes.

Novo Nordisk's weight-loss drug, Wegovy, has reportedly generated a waiting list of 10,000 patients in the United Kingdom, indicating significant demand for the medication.

A new test helps individuals determine their candidacy for prescription weight-loss drugs like Ozempic, Wegovy, and Mounjaro, which are now available for diabetes and obesity treatment.

A new generation of weight-loss therapies is under development, promising to offer improved efficacy and convenience compared to existing GLP-1 drugs like Zepbound and Wegovy.

Denmark is launching a study to explore whether the weight-loss drug Wegovy can contribute to increasing the number of people in the workforce.

Novo Nordisk is reportedly catching up to Eli Lilly, with its Wegovy pill potentially fueling a stock rally for the company.

New data from pharmaceutical company Novo Nordisk indicates that Wegovy (semaglutide 2.4 mg and 7.2 mg) provides significant and consistent weight loss results in women with obesity across all reproductive stages.

The anti-obesity medications Wegovy and Mounjaro are expected to be partially covered for patients suffering from severe obesity in France.

Bank of America analysts suggest Hims & Hers faces a significant challenge to meet its 2026 financial guidance, citing potential churn risk related to the weight-loss drug Wegovy.

Experts suggest that the rapid increase in the use of weight-loss drugs like Wegovy is significantly altering perceptions of attractiveness and beauty standards.

An EU authority has recommended the approval of the weight-loss pill Wegovy, which would make it the first new tablet-form slimming drug available on the European market.

Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.

New research indicates that individuals exhibit diverse responses to GLP-1 drugs like Wegovy, with some being "super-responders" while others show no effect.

Pharmac has included Wegovy, a medication for weight loss, on its list for future funding consideration; currently, the drug costs approximately $400 per month for individuals.

Novo Nordisk has announced new positive results for a higher dosage of its well-known weight-loss medication, Wegovy, indicating improved efficacy.

The CEO of Novo Nordisk, maker of Ozempic and Wegovy, stated that the drugmaker is more actively pursuing deals than ever before, indicating a strategic focus on mergers and acquisitions.

Amid a recent surge in usage, a guide has been published detailing the five best sites to safely purchase popular GLP-1 medications like Wegovy and Ozempic online without a traditional prescription.

Millions of patients have lost coverage for popular obesity drugs like Zepbound and Wegovy over the past year due to new restrictions, forcing many to seek alternative treatments.

American pharmaceutical company Eli Lilly has launched a new weight-loss drug, intensifying competition with Novo Nordisk's popular Wegovy. Experts believe the Danish pharmaceutical company remains strong in the battle for market share.

Eli Lilly is losing market share in India's GLP-1 market due to the influx of cheap semaglutide generics, while Novo Nordisk maintains its position through price cuts for Ozempic and Wegovy.

The patent for semaglutide, the active ingredient in Ozempic and Wegovy, expired in several countries, leading to a surge of cheap generic versions in Asia. This development has raised concerns about potential weight-loss abuse.

Novo Nordisk's new Wegovy pill has seen an explosive launch, drawing a new wave of patients into GLP-1 weight loss treatments. CNBC interviewed five U.S. patients who shared their varying initial experiences with the drug following its introduction.

The British health system is set to expand its offering of the weight-loss drug Wegovy to more than one million overweight patients who are at risk of heart attacks.

Scientists are scrutinizing weight-loss drugs like Wegovy, which have revolutionized medicine, to investigate a rare but potential risk of eye damage, as their growing popularity raises new safety questions.

New studies indicate that Wegovy, a widely used obesity medication, may be linked to a rare but severe complication known as 'eye stroke,' which can lead to sudden vision loss.

Novo Nordisk's higher dose version of its weight-loss drug Wegovy has received approval in the U.S., expanding treatment options for patients.

Novo Nordisk’s 7.2 mg dose of Wegovy will compete against Lilly’s GLP-1 injection.

Novo Nordisk Hellas announces the price reduction of the product Wegovy® according to the following table, effective March 18, 2026.

Novo Nordisk is appealing the decision to deny a subsidy for its obesity drug Wegovy in Sweden. The company is challenging the ruling that impacts the accessibility of the medication.

Leki przeciwcukrzycowe, takie jak Ozempic i Wegovy, zyskały w ostatnim czasie ogromną popularność jako środki na odchudzanie.

A major holder of shares in Novo Nordisk, the maker of Wegovy, saw their asset value cut by a third following a crash related to the company's performance.

Patients taking Wegovy are five times more at risk of sudden vision loss compared to those taking Ozempic, a new large study has shown.

The weight-loss jab Wegovy may carry the highest risk of sudden sight loss compared to other semaglutide drugs such as Ozempic, according to new analysis.

Cheap semaglutide, the drug in Ozempic and Wegovy, could help millions with diabetes and obesity in 160 countries Weight-loss jabs such as Wegovy and Ozempic could be made for just $3 a month,…

Forskarar trur at slankemedisinen Wegovy kan hjelpe med både vekt, hukommelse og den mentale helsa.

Novo Nordisk has commenced a €432 million upgrade of its facility in Ireland to boost the production of oral Wegovy.

Novo Nordisk gør klar til at producere blandt andet Wegovy på pilleform på nye anlæg i Irland.